Brief: Tcr2 Therapeutics Inc Files Prospectus Supplement Related To Offering Of Common Stock Up To $100 Million - SEC Filing
30/04/2021 21:51
April 30 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR2 THERAPEUTICS INC FILES PROSPECTUS SUPPLEMENT RELATED
TO
OFFERING OF COMMON STOCK UP TO $100 MILLION - SEC FILING
Source text for Eikon: [https://bit.ly/3e7u22g]
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview